Tradestie Institutional Equity Comparison Engine
ANNX vs ALXO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANNX Overall Edge
ANNX Captures Institutional Edge (2โ0 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ALXO at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against ALXO sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ANNX N/M vs ALXO N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
ANNX
1Y +28.6% vs -27.2% ยท 52W Pos 18% vs 8%
Options & Structure Winner
ANNX
BREAKDOWN (100th %ile IV) vs BREAKDOWN (36th %ile IV)
ANNX
NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap
$747.8M
1M Return
-13.09%
1Y Return
+28.6%
Forward P/E
N/M
Unified AI Score
43.5 / 100
HOLD
Tech 37.0
Fund 55.0
Flow 72.0
Mom 60.0
ALXO
NASDAQ
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.00
+0.5% 1D
Market Cap
$143.8M
1M Return
-11.84%
1Y Return
-27.17%
Forward P/E
N/M
Unified AI Score
54.1 / 100
HOLD
Tech 45.0
Fund 57.0
Flow 66.0
Mom 70.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ANNX +28.6%
ALXO -27.17%
Spread: +55.77 pp (ANNX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ANNX TTM Op. Margin: 0.0%
ALXO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs ALXO. Trailing 12-month operating profitability (ANNX 0.0% vs ALXO 0.0%) and valuation multiples (ANNX N/M vs ALXO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANNX | ALXO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $747.8M | $143.8M | Larger Scale | ANNX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | ANNX |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -130.8% | -80.7% | Higher ROE | ALXO |
| 52-Week Range Position Momentum | 18% ($3โ$7) | 8% ($1โ$3) | Stronger Trend | ANNX |
| Beta / 30D Volatility Risk Regime | 1.69ฮฒ ยท 63% Vol | 1.39ฮฒ ยท 111% Vol | Lower Realized Risk | ANNX |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 54.1 / 100 (HOLD) | Higher Composite | ALXO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ANNX vs ALXO Buy Guide
ANNX
BREAKDOWN
88d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
ALXO
BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
36th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ANNX nor ALXO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.